Research Papers:

LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma

Bing Liu, Yifei Chen and Jiong Yang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:24275-24291. https://doi.org/10.18632/oncotarget.13651

Metrics: PDF 2677 views  |   HTML 2717 views  |   ?  


Bing Liu1,*, Yifei Chen1,*, Jiong Yang1

1Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

*These authors contributed equally to this work

Correspondence to:

Jiong Yang, email: [email protected]

Keywords: lung squamous cell carcinoma, lung adenocarcinoma, long non-coding RNA, overall survival, gene regulation

Received: August 08, 2016     Accepted: November 14, 2016     Published: November 26, 2016


Long non-coding RNAs (lncRNAs) have been implicated in pathogenesis of various cancers, including lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). We used cBioPortal to analyze lncRNA alteration frequencies and their ability to predict overall survival (OS) using 504 LUSC and 522 LUAD samples from The Cancer Genome Atlas (TCGA) database. In LUSC, 624 lncRNAs had alteration rates > 1% and 64 > 10%. In LUAD 625 lncRNAs had alteration rates > 1% and 36 > 10%. Among those, 620 lncRNAs had alteration frequencies > 1% in both LUSC and LUAD, while 22 were LUSC-specific and 23 were LUAD-specific. Twenty lncRNAs had alteration frequencies > 10% in both LUSC and LUAD, while 44 were LUSC-specific and 16 were LUAD specific. Genome ontology and pathway analyses produced similar results for LUSC and LUAD. Two lncRNAs (IGF2BP2-AS1 and DGCR5) correlated with better OS in LUSC, and three (MIR31HG, CDKN2A-AS1 and LINC01600) predicted poor OS in LUAD. Chip-seq and luciferase reporter assays identified potential IGF2BP2-AS1, DGCR5 and LINC01600 promoters and enhancers. This study presented lncRNA landscapes and revealed differentially expressed, highly altered lncRNAs in LUSC and LUAD. LncRNAs that act as oncogenes and lncRNA-regulating transcription factors provide novel targets for anti-lung cancer therapeutics.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13651